![The World in 2021: A Conversation With Thomas Kurian](/sites/default/files/oembed_thumbnails/jggxMGO62MYXyrM_N9VcGj45h3aZRImvwPNY5t3FPYc.jpg)
The World in 2021: A Conversation With Thomas Kurian
![Creating Opportunities: A Conversation with Roshni Nadar Malhotra](/sites/default/files/oembed_thumbnails/qJJhOpShcpuGxHhDgLO1TqAzoyhlLNAYFaQUHwjcfRc.jpg)
Creating Opportunities: A Conversation with Roshni Nadar Malhotra
![Stronger Tomorrow: A Conversation with Julie Sweet](/sites/default/files/oembed_thumbnails/W2LZ_EGsiJ2xB06hfG7RUqWUMeilcfvfxF19bQnCH1E.jpg)
Stronger Tomorrow: A Conversation with Julie Sweet
![A Conversation with Dr. Francis Collins, Director, National Institutes of Health](/sites/default/files/oembed_thumbnails/su3vAFwSXwb_bW8760fX1RjwUdDovwlF7_F1Rk2-LIA.jpg)
A Conversation with Dr. Francis Collins, Director, National Institutes of Health
![Discussion Draft of the Pandemic and All-Hazards Preparedness Act (PAHPA) Reauthorization](/themes/custom/milken_emulsify/images/default-search-thumbnail.png)
Discussion Draft of the Pandemic and All-Hazards Preparedness Act (PAHPA) Reauthorization
![Request for Information on implementation of the Community Disaster Resilience Zones Act of 2022 – Federal Register Document Citation 88‐FR‐34171](/themes/custom/milken_emulsify/images/default-search-thumbnail.png)
Request for Information on implementation of the Community Disaster Resilience Zones Act of 2022 – Federal Register Document Citation 88‐FR‐34171
![Comments on FDA’s Draft Guidance for Industry, Investigators, and Other Stakeholders on Decentralized Clinical Trials for Drugs, Biological Products, and Devices - Docket ID FDA-2022-D-2870](/themes/custom/milken_emulsify/images/default-search-thumbnail.png)
Comments on FDA’s Draft Guidance for Industry, Investigators, and Other Stakeholders on Decentralized Clinical Trials for Drugs, Biological Products, and Devices - Docket ID FDA-2022-D-2870
![Robert Blaine - Stories from the Field](/themes/custom/milken_emulsify/images/default-search-thumbnail.png)